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From receptor binding kinetics to 
signal transduction; a missing link 
in predicting in vivo drug-action
Indira Nederpelt1, Maria Kuzikov2, Wilbert E. A. de Witte4, Patrick Schnider3, Bruno Tuijt1, 
Sheraz Gul  2, Adriaan P. IJzerman  1, Elizabeth C. M. de Lange4 & Laura H. Heitman  1
An important question in drug discovery is how to overcome the significant challenge of high drug 
attrition rates due to lack of efficacy and safety. A missing link in the understanding of determinants for 
drug efficacy is the relation between drug-target binding kinetics and signal transduction, particularly 
in the physiological context of (multiple) endogenous ligands. We hypothesized that the kinetic 
binding parameters of both drug and endogenous ligand play a crucial role in determining cellular 
responses, using the NK1 receptor as a model system. We demonstrated that the binding kinetics 
of both antagonists (DFA and aprepitant) and endogenous agonists (NKA and SP) have significantly 
different effects on signal transduction profiles, i.e. potency values, in vitro efficacy values and onset 
rate of signal transduction. The antagonistic effects were most efficacious with slowly dissociating 
aprepitant and slowly associating NKA while the combination of rapidly dissociating DFA and rapidly 
associating SP had less significant effects on the signal transduction profiles. These results were 
consistent throughout different kinetic assays and cellular backgrounds. We conclude that knowledge 
of the relationship between in vitro drug-target binding kinetics and cellular responses is important to 
ultimately improve the understanding of drug efficacy in vivo.
Drug discovery is consistently challenged with overcoming high attrition rates due to lack of efficacy and safety 
in clinical trials. In the past decade, numerous researchers have proposed drug-target binding kinetics (i.e. asso-
ciation and dissociation rates) as important in vitro parameters and have suggested to include these early in the 
drug discovery paradigm1–4. While plasma pharmacokinetic profiles are relatively well understood, and progress 
is made in understanding and predicting target tissue distribution and target occupancy5–7, the crucial step from 
drug-target binding kinetics to the in vivo cellular response that precedes the entire body’s response is typically 
missing (Fig. 1). Since these responses cannot yet be measured in the living body, we resort to using in vitro 
systems that reflect the in vivo conditions as closely as possible. So far, numerous receptor binding assays, such 
as radioligand binding8, surface plasmon resonance (SPR), surface acoustic wave (SAW)9, and time-resolved 
fluorescence resonance energy transfer (TR-FRET) assays10, have been designed and validated to study binding 
kinetics at the receptor level. However, there is a need for kinetic functional assays to better predict in vivo cellular 
responses of kinetically diverse compounds. Functional assays that are well suited for this purpose include the 
real-time GloSensor™ cAMP assay11,12, measuring cAMP production, and the real-time impedance-based xCEL-
Ligence™ assay13,14, that measures changes in cell morphology as a more integral cellular response.
The neurokinin 1 (NK1) receptor is an example of a target for which drugs with optimal binding kinetics are 
reported. It is mainly expressed in the central nervous system (CNS) and has been suggested to play a role in the 
regulation of affective behavior and emesis in the brain, as well as nociception in the spinal cord15,16. While a 
plethora of NK1 antagonists have been synthesized17–19, most antagonists have failed in the clinic due to a reported 
lack of efficacy20,21. Currently, two small molecule NK1 antagonists are marketed to treat chemotherapy-induced 
emesis and nausea, namely aprepitant and netupitant. A study by Hale et al. indicated that aprepitant is superior 
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to other NK1 receptor antagonists due to its slow receptor dissociation rate of 0.0054 min−1 at room tempera-
ture22. These results were confirmed in a later study in which the long-lasting in vivo effects of aprepitant were 
directly related to its slow dissociation rate rather than a long half-life23. More recently, the highly selective NK1 
antagonist netupitant, in combination with a serotonin 5-HT3 receptor antagonist, was approved by the FDA24. 
Similar to aprepitant, netupitant was considered insurmountable, i.e. able to depress the maximal agonist-induced 
response by preventing agonist rebinding, and shown resistant to wash-out experiments, i.e. during wash-out 
netupitant was still tightly bound to the receptor25. The authors proposed slow receptor dissociation kinetics as 
the mechanism hereof.
Another important aspect in in vivo receptor binding is competition of the drug with endogenous ligands. 
It is therefore crucial to study the binding kinetics and subsequent cellular responses of drug candidates in the 
presence of such endogenous ligands, as the binding kinetics of these competing endogenous ligands can be sub-
stantially different26. For example, the binding kinetics of endogenous NK1 receptor ligands, called tachykinins, 
such as substance P (SP) and neurokinin A (NKA) have been found to have very divergent binding kinetics27. The 
necessity of slow receptor binding kinetics of NK1 receptor antagonists to achieve high in vivo efficacy in addition 
to the varying binding kinetics of the endogenous tachykinins, i.e. NKA and SP, makes the NK1 receptor a good 
model system to examine distinct kinetic interactions of antagonist and agonist binding and its effects on signal 
transduction.
In this study we hypothesized that the kinetic binding parameters of both the drug and the endogenous ligand 
play a crucial role in determining cellular responses. Hence, the in vitro functional effects of receptor binding 
kinetics were examined for kinetically divergent agonists and antagonists using the NK1 receptor as a model 
system. We report differential signal transduction profiles dependent on the kinetic binding characteristics of 
antagonists and endogenous agonists. The results were congruous throughout varying assay temperatures, cellu-
lar backgrounds, kinetic assays and a novel approach studying the onset of receptor activation. We provide, for 
the first time, a translation of target binding kinetics into kinetic cellular responses enabling better predictions of 
in vivo drug effects.
Results
Aprepitant and DFA have very divergent binding kinetics at the NK1 receptor. The kinetic bind-
ing parameters of 87 small molecule NK1 receptor antagonists were determined using a qualitative kinetic screen-
ing method, namely a dual-point competition association assay (data not shown). These experiments yielded 
kinetic rate index (KRI) values ranging from 0.7 ± 0.18, to 2.0 ± 0.18, i.e. indicating faster and slower dissociation 
kinetics in comparison to the radioligand [3H][Sar9,Met(O2)11]SP, respectively. Aprepitant (KRI of 1.8 ± 0.10) and 
desfluoro aprepitant (DFA) (KRI of 1.0 ± 0.13) were selected for further studies as they had the highest chemical 
similarity combined with the most divergent binding kinetics (Supplemental Fig. 1 and Table 1).
Real-time functional effects of NK1 receptor activation by SP and NKA are comparable 
between kinetic assays. The cellular response to NK1 receptor activation was monitored using two 
real-time assays, namely a cAMP assay (GloSensor) and a morphology-based assay (xCELLigence). A 
time-dependent and concentration-dependent increase in cAMP production was observed with the GloSensor 
assay for both endogenous agonists SP and NKA with a maximal cAMP value around 20 to 30 minutes after stim-
ulation (Fig. 2A,B). These experiments yielded EC50 values for SP and NKA of 2.2 ± 0.5 nM and 483 ± 142 nM, 
respectively (Tables 2 and 3). Similarly, upon SP or NKA stimulation cellular impedance was increased time- 
and concentration-dependently with a peak response around 20–30 minutes (Fig. 2C,D), with EC50 values of 
Figure 1. Schematic overview of factors involved between drug dosing and body responses, i.e. drug effects. 
While drug dosing, plasma pharmacokinetics, target tissue distribution, intra-tissue or target site distribution, 
cellular signal transduction and body responses are often examined drug-target binding kinetics are often 
disregarded. More importantly, elucidation of the pivotal step, i.e. effects of binding kinetics on signal 
transduction, from drug-target binding kinetics to in vivo drug responses is highly desirable.
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0.026 ± 0.004 nM for SP and 3.9 ± 1.1 nM for NKA (Table 2). Potency values obtained with the morphology assay 
were systematically higher in comparison to the cAMP assay.
Aprepitant is more effective in decreasing SP-mediated maximal response. To investigate the 
antagonistic effects of aprepitant and DFA on SP-mediated NK1 receptor activation, cells were pre-incubated 
with varying concentrations of antagonist prior to stimulation with SP. In the cAMP assay both antagonists were 
unable to significantly shift the EC50 of SP, however the Emax of SP was significantly decreased (Fig. 3A,B, Table 2). 
At the highest concentrations, aprepitant was more efficacious in lowering the Emax than DFA, abolishing it over 
80% in comparison to control while DFA only decreased the Emax by 39% (Table 2). Interestingly, in the morphol-
ogy assay both antagonists did decrease the EC50 of SP to 3.0 ± 1.3 nM for DFA and 0.23 ± 0.08 nM for aprepitant 
(Fig. 3C,D, Table 1). Similar to the cAMP assay, the Emax of SP was significantly reduced by the antagonists to 
82 ± 6.9% in presence of DFA and to a larger extent for aprepitant to 53 ± 8.5% (Table 2). Moreover, IC50 values 
were examined by pre-incubating increasing concentrations of antagonist prior to addition of EC80 concentra-
tions of agonist (Fig. 4). This resulted in IC50 values of 0.15 ± 0.02 nM (cAMP assay) and 0.22 ± 0.1 nM (morphol-
ogy assay) for DFA. IC50 values for aprepitant were comparable to DFA with 0.19 ± 0.07 nM and 0.58 ± 0.22 nM 
from the cAMP and morphology assay, respectively.
Antagonistic effects were more pronounced upon NKA-mediated receptor activation. The 
inhibitory effects of both antagonists were also investigated for NKA-mediated NK1 receptor activation. In the 
cAMP assay, aprepitant was able to decrease the potency of NKA by 10-fold, while DFA did not affect the ago-
nist potency (Fig. 3E,F, Table 2). This is markedly different from the results observed with SP-mediated receptor 
activation. Conversely, both antagonists lowered the maximal effect of NKA, while aprepitant was most effective 
and lowered the Emax to 7.8 ± 4.2% (Table 2) and similar to SP-mediated receptor activation. With the xCELLi-
gence, the highest concentrations of both antagonists increased the EC50 values by 2-fold for DFA and 7-fold for 
aprepitant (Fig. 3G,H, Table 2). Similar to the cAMP assay, both antagonists decreased the maximal effect of NKA 
pKi kon (nM−1 min−1) koff (min−1) KRI
SP* 8.7 ± 0.01 0.24 ± 0.046 0.027 ± 0.0025 N.A.
NKA* 5.7 ± 0.04 0.0010 ± 0.00018 0.19 ± 0.036 N.A.
DFA 9.3 ± 0.04 N.A. N.A. 1.0 ± 0.13
Aprepitant 9.5 ± 0.11 N.A. N.A. 1.8 ± 0.10
Table 1. Affinity and kinetic binding parameters of SP, NKA, DFA and aprepitant. Values are means ± SEM of 
at least three separate experiments performed in duplicate. *Data have been previously published in27.
Figure 2. Real-time NK1 receptor-mediated responses monitored with cAMP (A and B) or morphology  
(C and D) experiments induced by addition of increasing concentrations of endogenous agonist SP (A and C) or 
NKA (B and D). Representative graph of at least three experiments performed in duplicate (morphology assays) 
or triplicate (cAMP assays). RLU stands for relative light units and NCI stands for normalized cell index.
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while aprepitant was more efficacious (30 ± 6.2%) than DFA (81 ± 8.9%) (Table 2). Furthermore, pretreatment of 
increasing concentrations of antagonist prior to addition of EC80 concentrations of agonist resulted in IC50 values 
ranging from 0.26 ± 0.08 nM (cAMP) to 0.12 ± 0.006 nM (morphology) for DFA while IC50 values for aprepitant 
ranged from 0.23 ± 0.09 nM (cAMP) to 0.43 ± 0.07 nM (morphology) (Fig. 4). IC50 values of aprepitant and DFA 
obtained from the two assays were similar.
Aprepitant caused a reduced rate of NK1 receptor activation induced by NKA and SP. To exam-
ine the real-time effects of DFA and aprepitant on the inhibition of the cellular response to NK1 receptor activa-
tion, a novel analysis method was designed to examine the onset of receptor activation. The increase in cAMP 
production within the first 8 minutes after addition of the endogenous agonist was compared in the presence and 
absence (control) of an antagonist. The onset of SP-induced cAMP production was significantly decreased (i.e. 
up to 6-fold) upon pre-incubation with aprepitant but not with DFA (Fig. 5A–C, Table 3). Similarly, the onset of 
SP-induced impedance changes was significantly decreased 5-fold upon aprepitant pretreatment, while pretreat-
ment with DFA was less significant (Fig. 5D,E, Table 3). Moreover, the ability of aprepitant to reduce the onset of 
receptor activation was more pronounced for NKA, where a significant 15-fold decrease in onset was observed 
in cAMP production and a significant 8-fold decrease for morphological changes (Fig. 5F–I Table 3). Conversely, 
DFA did not significantly decrease the onset of receptor activation in both cAMP and morphology assays.
Discussion
To our knowledge, we are the first to provide an extensive investigation for the in vitro cellular responses in rela-
tion to receptor binding kinetics of antagonists and endogenous agonists. This research has significant implica-
tions for the understanding of signal transduction induced by kinetically diverse ligand-receptor interactions and 
the interplay between endogenous agonists and drugs targeting the receptor of interest.
EC50 (nM) Emax (%)
cAMP morphology cAMP morphology
SP NKA SP NKA SP NKA SP NKA
Agonist 2.2 ± 0.5 483 ± 142 0.026 ± 0.004# 3.9 ± 1.1# 100 ± 5.1 100 ± 7.7 100 ± 0.95# 100 ± 0.44#
+0.07 nM DFA 1.9 ± 0.5NS 399 ± 19NS 0.053 ± 0.020NS 3.0 ± 0.52NS 78 ± 4.5* 84 ± 18NS 97 ± 5.6NS 109 ± 7.6NS
+0.21 nM DFA 2.7 ± 0.8NS 304 ± 89NS 0.06 ± 0.015* 3.3 ± 0.45NS 75 ± 7.7* 67 ± 10* 104 ± 4.2NS 108 ± 6.7NS
+0.7 nM DFA 2.3 ± 0.7NS 1080 ± 356NS 3.0 ± 1.3* 8.5 ± 0.46* 61 ± 10** 61 ± 15* 82 ± 6.9** 81 ± 8.9**
+0.07 nM 
aprepitant 1.6 ± 0.2
NS 1008 ± 165NS 0.022 ± 0.008NS 5.0 ± 1.7NS 62 ± 5.7** 71 ± 13NS 96 ± 7.6NS 97 ± 2.3NS
+0.21 nM 
aprepitant 8.8 + 5.4
NS 1051 ± 170* 0.11 ± 0.01**** 8.0 ± 2.8NS 55 ± 15** 43 ± 19** 79 ± 5.0*** 79 ± 10**
+0.7 nM 
aprepitant 1.3 ± 0.3
NS 4370 ± 524*** 0.23 ± 0.08** 26 ± 6.8** 19 ± 5.5**** 7.8 ± 4.2**** 53 ± 8.5**** 30 ± 6.2****
Table 2. Potency and maximal effect values of SP with or without antagonist pre-incubation determined 
with cAMP or morphology assays. Values are means ± SEM of at least three separate experiments performed 
in duplicate (morphology) or triplicate (cAMP). Values were calculated with peak analysis and data were 
normalized to maximal response obtained for SP or NKA only. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001 compared to SP or NKA, determined using one-way ANOVA with Dunnett’s post-test. #Data 
have been previously published in27.
cAMP (RLU min−1)# Morphology (NCI min−1)#
SP NKA SP NKA
Agonist 215 ± 37 147 ± 35 0.05 ± 0.004 0.05 ± 0.004
+0.07 nM DFA 125 ± 31NS 98 ± 29NS 0.06 ± 0.006NS 0.06 ± 0.005NS
+0.21 nM DFA 120 ± 27NS 98 ± 33NS 0.05 ± 0.006NS 0.05 ± 0.007NS
+0.7 nM DFA 158 ± 26NS 71 ± 22NS 0.03 ± 0.005* 0.04 ± 0.014NS
+0.07 nM 
aprepitant 94 ± 13* 75 ± 13
NS 0.05 ± 0.002NS 0.05 ± 0.011NS
+0.21 nM 
aprepitant 63 ± 17** 43 ± 7.7* 0.04 ± 0.006
NS 0.03 ± 0.007NS
+0.7 nM 
aprepitant 36 ± 7** 9.7 ± 1.6** 0.009 ± 0.003**** 0.006 ± 0.003**
Table 3. Onset of SP- or NKA-induced receptor activation after pretreatment with DFA or aprepitant 
determined with cAMP or morphology assays. Values are means ± SEM of at least three separate experiments 
performed in duplicates (morphology) or triplicates (cAMP). The onset of receptor activation was calculated on 
the first 8 min after agonist stimulation. #RLU stands for relative light units and NCI stands for normalized cell 
index. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared to agonist only, determined using one-
way ANOVA with Dunnett’s post-test.
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The NK1 receptor is an interesting target for the treatment of neurological disorders and currently two drugs, 
aprepitant and netupitant, are approved for the treatment of chemotherapy induced emesis28. While the high 
in vivo efficacy of aprepitant is attributed to its slow dissociation kinetics23, a mechanistic interpretation of the 
translation of binding kinetics to functional effects is lacking. Therefore, this study was designed to bridge the gap 
between receptor binding kinetics and functional effects in vitro, which is important for the understanding of the 
translation of in vitro to in vivo data.
We hypothesized that the slowly dissociating antagonist aprepitant would be more effective in antagonizing 
the receptor than its fast dissociating analogue DFA. The rightward-shift in potency of SP and NKA was most 
discernable at the highest concentration of antagonist, where aprepitant increased the EC50 value and decreased 
the Emax value more significantly than DFA (Table 2, Fig. 3). Where aprepitant was fully insurmountable, DFA was 
only partially insurmountable. The latter can be explained by the fact that DFA is a faster dissociating compound 
when compared to aprepitant, but DFA is still a slower dissociating compound in comparison to the endogenous 
agonists SP and NKA. Hence, pre-incubation with DFA resulted in partially insurmountable antagonisms as 
opposed to surmountable antagonism with an even faster dissociating antagonist. Our results for aprepitant are 
Figure 3. Concentration-dependent effects induced by endogenous agonist SP pre-incubated with vehicle 
(control), DFA or aprepitant determined with cAMP (A and B) or morphology (C and D) experiments. 
Concentration-dependent effects induced by endogenous agonist NKA pre-incubated with vehicle (control) 
DFA or aprepitant determined with cAMP (E and F) or morphology (G and H) experiments. Representative 
graph of at least three experiments performed in duplicate (morphology assays) or triplicate (cAMP assays). 
RLU stands for relative light units and NCI stands for normalized cell index.
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in line with its previously reported insurmountable effects22. In the same study the ID50 values of aprepitant and 
DFA were determined in an animal model for CNS activity (gerbil foot tapping), where aprepitant was 3-fold 
more potent than its analogue DFA22. Another study examined the insurmountable effects of a close analogue of 
aprepitant and DFA, namely L-742,694. A clear decrease in Emax of SP after pre-incubation with L-742,694 was 
reported and this effect was associated with the slow dissociation rate of this antagonist from the NK1 receptor29. 
Altogether, these findings support our hypothesis that slowly dissociating antagonists are important for achieving 
a high in vivo efficacy by insurmountable antagonism at the NK1 receptor.
While both antagonists aprepitant and DFA were able to increase the EC50 and decrease Emax values for both 
NKA and SP, NKA was overall more sensitive to antagonism than SP. This supposed “probe-dependency”, i.e. 
observed effects are dependent on the probe (e.g. agonist) used, is already widely acknowledged in the field of 
allosteric modulation30,31, while this concept is rarely considered for orthosteric interactions. Interestingly, we 
have previously determined the binding kinetics of SP and NKA and found large differences in the association 
rates of both agonists, i.e. NKA associates 240-fold slower to the NK1 receptor than SP27. This slow association 
could be an explanation as to why NKA is more sensitive to antagonism, considering that both antagonists have 
more time to intervene with NKA target binding due to their assumed faster association rates, slower dissociation 
rates and pre-incubation time. The differential kinetics (and therefore sensitivity) of both endogenous agonists 
should be taken into account for further research towards the NK1 receptor and other GPCRs that have multiple 
endogenous ligands26.
A comparison between EC50 values obtained with the cAMP or morphology assays showed lower potency 
values for the latter. This is in line with other observations, namely that potency values acquired from label-free 
assays such as the xCELLigence are often reported to be much lower and may be attributed to the fact that 
these assays encompass the entire cellular response thereby accumulating multiple signaling pathways instead 
of only one32–34. Moreover, it appeared that the morphology assay was more sensitive to pick up shifts in 
potency upon antagonist treatment while the cAMP assay was most sensitive in detecting insurmountability, 
i.e. a decrease in maximal effect. A possible explanation could be the differences in assay set-up that can alter 
the assay sensitivity. For instance, morphology experiments are typically performed at 37 °C while cAMP 
assays were carried out at 25 °C. Lower assay temperatures result in slower dissociation rates which could 
explain the higher sensitivity of the cAMP assay to detect insurmountability. Moreover, the cAMP assay was 
carried out with CHOhNK1 cells while the morphology assay was performed with U-251 MG cells. Multiple 
studies have previously discussed the concept of receptor reserve, i.e. high receptor coupling efficiency and/
or high-receptor density35,36. It was proposed that tissue with essentially no receptor reserve treated with an 
insurmountable antagonist could present a decrease in maximal response with only a marginal rightward shift 
in potency. Heterologous cell lines are often reported to have higher receptor reserves in comparison to cell 
lines with endogenous expressions. However, our results suggest that U-251 MG cells have a higher receptor 
reserve than CHOhNK1 cells and U-251 MG cells might therefore be better suited to detect a shift in potency. 
These findings demonstrate the importance of choosing the appropriate assay and cell type for the aim of the 
research.
The functional effects of antagonist binding kinetics are often examined with insurmountability assays using 
end-point measurements37 but also real-time experiments38. Although a few studies have paid some attention to 
the real-time changes in cellular effects13,14,39,40, we are the first to report a quantitative analysis method for the 
real-time cellular responses induced by agonists with antagonist pre-incubations. In this study, we were able to 
correlate the kinetics of receptor activation (i.e. rate of onset) to receptor binding kinetics of antagonists. The 
slowly dissociating antagonist aprepitant was effective in not only significantly decreasing the maximal effect of 
SP and NKA but also in significantly reducing the onset of receptor activation, which would have been missed 
using a traditional end-point assay. Hence, this novel analysis provides a robust and time-efficient screening 
method to detect slowly dissociating antagonists using a real-time functional assay.
In conclusion, we confirmed our hypothesis that the kinetic binding parameters of both endogenous ligand 
and drug play an important role in defining cellular responses. We demonstrated that the binding kinetics of 
both antagonists and endogenous agonists have significantly different effects on signal transduction profiles, i.e. 
potency values, in vitro efficacy values and onset rate of signal transduction. Moreover, these findings were con-
sistent throughout different kinetic assays, assay temperatures and cellular backgrounds. We propose that incor-
porating real-time functional assays early in the drug discovery program will enable the detection of kinetically 
Figure 4. Concentration-dependent inhibition by DFA or aprepitant of EC80 concentrations of SP- or NKA- 
mediated receptor activation measured with morphology (A) or cAMP (B) experiments. Representative graph 
of at least three experiments performed in duplicate (morphology assays) or triplicate (cAMP assays). RLU 
stands for relative light units and NCI stands for normalized cell index.
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interesting compounds. Moreover, combining knowledge of binding kinetics and functional kinetics on drugs 
and endogenous ligands could improve predictions of in vivo drug action and thereby the success rate of drug 
discovery.
Figure 5. Time-dependent effects induced by EC80 concentration of SP after pre-incubation with DFA or 
aprepitant observed with cAMP assay (A). Zoom-in on first 8 minutes of time-dependent effects induced by EC80 
concentration of SP (B and C) or NKA (F and G) after pre-incubation with DFA or aprepitant determined with 
cAMP experiments. Representative graph of at least three experiments performed in triplicate. RLU stands for 
relative light units. Zoom-in on first 8 minutes of time-dependent effects induced by EC80 concentration of SP (D 
and E) or NKA (H and I) after pre-incubation with DFA or aprepitant determined with morphology experiments. 
Representative graph of at least three experiments performed in duplicate. NCI stands for normalized cell index.
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Methods
Reagents and compounds. SP and NKA were purchased from Sigma-Aldrich (St. Louis, MO) and 
Bio-Connect (Huissen, The Netherlands), respectively. All NK1 antagonists were synthesized in-house as 
described previously22. Chinese Hamster Ovary (CHO) cells stably expressing the human neurokinin 1 receptor 
(CHOhNK1 cells) were kindly provided by AstraZeneca (Macclesfield, UK) and U-251 MG cells were purchased 
from Sigma-Aldrich (St. Louis, MO). xCELLigence E-plate 16 and 96 were purchased from Westburg (Leusden, 
the Netherlands). pGloSensor™-22F cAMP plasmid, GloSensor™ cAMP reagent and FuGENE HD transfec-
tion reagent were obtained from Promega GmbH (Mannheim, Germany). CELLSTAR® 384-Well Plates, Tissue 
Culture Treated were purchased from Greiner Bio-One (Frickenhausen, Germany). [3H][Sar9,Met(O2)11]SP (spe-
cific activity 25–55 Ci/mmol) was obtained from Perkin Elmer (Boston, MA). All other reagents and materials 
were obtained from commercial resources.
Cell culture. U-251 MG cells were cultured in Earle’s Minimal Essential Medium (EMEM) supplemented 
with 10% FCS, 1 mM sodium pyruvate, 2 mM glutamine, 1% non-essential amino acids (NEAA), 100 IU/ml 
penicillin and 100 µg/ml streptomycin at 37 °C + 5% CO2. CHOhNK1 cells were cultured in Ham’s F12 medium 
supplemented with 10% fetal calf serum (FCS), 2 mM glutamine and 1 mg/ml G418 at 37 °C + 5% CO2.
Dual-point competition association assays. Dual-point competition association assays were per-
formed as prescribed previously41, following the radioligand binding protocol of Nederpelt et al.27. In short, 
CHOhNK1 membrane aliquots containing 5–15 µg protein were incubated at 4 °C with 25,000 cpm (~2.5 nM) 
[3H][Sar9,Met(O2)11]SP and one concentration of competing antagonist (i.e. concentration at which approxi-
mately 50% (30–70%) [3H][Sar9,Met(O2)11]SP binding was achieved). Specific binding of [3H][Sar9,Met(O2)11]
SP was determined at two time-points; 30 min (t1), which is the time-point at which equilibrium of [3H]
[Sar9,Met(O2)11]SP binding was achieved, and 120 min (t2) at which all competing antagonists should have 
reached equilibrium.
Impedance-based morphology assays. Label-free morphology assays were performed using the xCEL-
Ligence RTCA system as described previously27,42. U-251 MG cells were treated with three different concen-
trations (0.07 nM, 0.21 nM and 0.7 nM) of aprepitant or DFA for 30 min prior to stimulation with increasing 
concentrations of SP or NKA.
Real-time cAMP accumulation assay. Real-time cAMP production was measured using the life cell 
cAMP GloSensorTM assay11,12. The technology is based on a cAMP-biosensor, which undergoes a conformational 
change upon cAMP binding, followed by the turnover of Luciferin.
CHOhNK1 cells were transiently transfected with the pGloSensor™-22F cAMP (6 ng/µL) plasmid using 
FuGene HD (3 µL:1 µg DNA plasmid) as a transfection reagent. Accordingly, cells were harvested and reconstituted 
to 0.5 × 106 cells/ml (10,000 cells/well) in DMEM/F-12/ HEPES supplemented with 1% FCS, 2 mM glutamine and 
1 mg/ml G418. The diluted plasmid solution was combined with the transfection reagent and incubated for 20 min 
at room temperature. Subsequently, the transfection mixture and cell solution were mixed for additional 5 min 
before plating in 384-well plates. The transfected cells were incubated for 24 h at 37 °C + 5% CO2 followed by 
treatment with Glo-substrate (3% v/v) for 2 h at room temperature. Subsequently, three different concentrations 
(0.07 nM, 0.21 nM and 0.7 nM) of Aprepitant or DFA were added to cells for 30 min (pre-incubation) using Echo™ 
550 Liquid Handler (Labcyte), followed by addition of increasing concentrations of SP or NKA. Real-time changes 
in the level of cAMP were detected using an Envision HTS microplate reader 2103 (PerkinElmer).
Data analysis. All experimental data were analyzed using the curve-fitting program GraphPad Prism v. 6.00 
(GraphPad Software Inc., San Diego, CA).
Data from dual-point competition association assays were analyzed by dividing the specific binding at t1 (Bt1) 
with the specific binding at t2 (Bt2).
=KRI B /B (1)t1 t2
Data from morphology and cAMP experiments were analyzed as described previously27. Efficacy (Emax) and 
potency (pEC50) values for SP and NKA were analyzed with non-linear regression of peak analysis fitted by 
log(agonist) vs. response - Variable slope. Results were normalized to the maximal response induced by agonist 
without antagonist.
The onset of receptor activation was analyzed by calculating the slope with linear regression of the first 8 min-






All data are means of at least three separate experiments performed in duplicate or triplicate. Statistical analy-
sis was performed using one-way ANOVA with Dunnett’s post-test.
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